Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
GLP-1 agonists reduce hepatic steatosis primarily through weight loss, improved insulin sensitivity, and decreased hepatic glucose production and lipogenesis
The primary endpoints for this study were change in body weight and body composition (assessed by dual x-ray absorptiometry [DXA] scanning for total mass, fat mass, and lean mass), and we also assessed food intake, glycated hemoglobin (HbA1c%), and lipid profiles
J Clin Endocrinol Metab 63: 492-498, 1986
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
US$ 20.45
US$ 27.78
US$ 27.58
US$ 28.57
US$ 28.02
US$ 19.99
